Where does Nexalin Technology, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nexalin Technology, Inc. ranks #41,935 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nexalin Technology, Inc. hold?

Nexalin Technology, Inc. holds 6 US utility patents granted between 2024 and 2025, spanning 2 technology areas.

What is Nexalin Technology, Inc.'s Innovation Score?

Nexalin Technology, Inc. has an Innovation Score of 38.0 out of 100 (top 42% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nexalin Technology, Inc. focus on?

Nexalin Technology, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 4 patents, ranking #794 of 1,943 assignees active in that subclass. Grants appear in 2 CPC subclasses total.

Is Nexalin Technology, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Nexalin Technology, Inc..

What does claim depth mean for Nexalin Technology, Inc.'s patents?

Nexalin Technology, Inc.'s patents average 10.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nexalin Technology, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Nexalin Technology, Inc.

USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nexalin ranks #41,935 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 2 technology areas.

#41,935
of 49,997 US assignees by volume: Top 42%
by Innovation Score (38.0/100): 10.5
avg claims per patent

USPTO PatentsView assignee plate

Corpus R41935 · US Corporation #41,935 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #41,935/49,997
PHOTO-FINISH NEW Paradigm Group
CPC-NARROW A61N · 2 areas
INNOV-THIN 38.0/100
CLAIMS-PAR 10.5 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2024–2025 · 2y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: NEW Paradigm Group, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nexalin’s 38.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (18%) Velocity 20.0 pts (53%) Breadth 5.0 pts (13%) Claim depth 6.3 pts (17%)

Qualcomm Incorporated · highest

85
Nexalin Technology · this assignee

38
3D Lighting… · lowest

7

What this shows Nexalin's Innovation Score is 38.0/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nexalin?

Each dot is one of Nexalin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nexalin’s own 10.5 claims/patent is at or below the 11.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Nexalin vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nexalin's grants concentrate

Nexalin Technology, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 66.7% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). By volume, Nexalin sits between NEW Paradigm Group, LLC and NGCodec Inc..

Nexalin's three-year grant acceleration

Nexalin Technology, Inc. shows 3 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

NEW Paradigm Group

6
Newtec CY

6
Newtech Textile T…

6
Newvastek

6
Nextkidney

6
Nexus Industries

6
NG Imports

6
Ngcodec

6
Nexalin Technology ◀

6

What this shows Nexalin holds 6 patents at rank #41,853, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nexalin

By rank, the assignees closest to #41,853 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Nexalin's primary technology class.

Nexalin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 42% higher than 58% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table

Nexalin Technology, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2024	3	50.0%
2025partial year	3	50.0%

Which technologies does Nexalin Technology, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 4

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

Top 2 of 2 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nexalin Technology, Inc.'s patent record in context - here's where to go next.

Nexalin Technology, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 66.7% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #41,935 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nexalin Technology, Inc. against NEW Paradigm Group, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.